New Alzheimer’s Trial Reveals Surprising Insight on Brain Health

Novo Nordisk, the pharmaceutical company behind popular GLP-1 medications like Wegovy and Ozempic, recently announced that its phase 3, two-year trial examining GLP-1 medications for Alzheimer's failed to produce a significant reduction in disease progression.While these results are discouraging, they may have revealed something vital about Alzheimer’s treatment.In this video, Dr. Bret Scher breaks down the recent failure of Novo Nordisk’s evoke and evoke+ trials and what it teaches us about the limitations of a drug-only approach to Alzheimer’s treatment.Key topics covered:Why GLP-1s may not be enough for Alzheimer’sThe link between glucose metabolism and brain energy failureHow ketones offer an alternative fuel for the brainEarly research on ketogenic therapy for cognitive impairmentWhy nutritional interventions deserve more scientific attentionWith Alzheimer’s affecting millions and costing billions, it’s time to shine a light on metabolic strategies that directly support brain energy, reduce inflammation, and improve cognitive function.🧠 Explore our full playlist on ketogenic therapy for Alzheimer’s and cognitive decline: https://www.youtube.com/playlist?list=PLzWI83-NWCL4f7uVRIWUHCC2nF6t_5DLw#MetabolicMind #KetogenicTherapy #AlzheimersExpert Featured:Dr. Bret ScherBaszucki Group Medical Directorhttps://x.com/bschermdResources Mentioned:Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progressionhttps://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916462#Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real-world data in the UShttps://doi.org/10.1002/alz.14313Brain energy rescue with ketones improves cognitive outcomes in MCIhttps://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.059627Randomized crossover trial of a modified ketogenic diet in Alzheimer's diseasehttps://pubmed.ncbi.nlm.nih.gov/33622392/Ketogenic strategies for Alzheimer’s disease and other memory impairments: History, rationale, and 288 caregiver case reportshttps://esmed.org/MRA/mra/article/view/5316Metabolic Mind Ketogenic Therapy for Dementia Playlisthttps://www.youtube.com/playlist?list=PLzWI83-NWCL4f7uVRIWUHCC2nF6t_5DLwFree CME Clinician Trainings:Are you a clinician who would like to learn more about the science behind these therapies and how to implement them in practice? Earn CME with our growing library of courses from some of the top experts in the field including Dr. Chris Palmer, Dr. Georgia Ede, Dr. Matthew Bernstein and Dr. Bret Scher with more coming soon.Our courses have been made FREE by grants from Baszucki Group, so we can spread these powerful therapies as widely as possible. Earn CME/CNE credits:https://www.metabolicmind.org/for-clinicians/trainings-courses/?utm_medium=organic-social&utm_source=youtube&utm_campaign=cme-ytFollow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.